C-EOYZTOR Therapeutics
mTORC1 inhibition, fixed-dose combination, neuroinflammation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EOYZ
C-EOYZC-EOYZmTORC1 inhibition, fixed-dose combination, neuroinflammation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TOR Therapeutics states that its mission is healthy aging and that Alzheimer's disease should be treated as early as possible, before irreversible brain destruction occurs. The company believes abnormal amyloid and tau accumulation drives neuroinflammation and later cognitive decline, and that an oral fixed-dose combination of two mTORC1 inhibitors could help maintain cognitive function in early Alzheimer's disease while also addressing disorders linked to mTORC1 hyperactivation.
SourceTOR Therapeutics states that aging-related diseases, especially Alzheimer's disease, should be addressed as early as possible before irreversible brain destruction occurs. The company believes abnormal amyloid and tau accumulation drives neuroinflammation and later cognitive decline, and that a fixed-dose combination of two mTORC1 inhibitors could help maintain cognitive function in early Alzheimer's while also benefiting other disorders linked to mTORC1 hyperactivation. It also frames anti-aging and anti-inflammatory effects as important ways to fight neurodegeneration.
SourceTOR Therapeutics states that its mission is healthy aging and that Alzheimer's disease should be treated as early as possible, before irreversible brain destruction occurs. The company believes abnormal amyloid and tau accumulation drives neuroinflammation and later cognitive decline, that many at-risk people can now be identified earlier through new blood tests, and that a fixed-dose combination of two mTORC1 inhibitors with anti-aging and anti-inflammatory properties may help maintain cognitive function in early Alzheimer's disease and other disorders driven by mTORC1 hyperactivation.
SourceTOR Therapeutics states that its mission is healthy aging and that diseases of aging, especially Alzheimer's disease and cancer, should be addressed early through prevention-focused treatment. The company argues that Alzheimer's develops over decades through amyloid and tau accumulation that drives neuroinflammation and irreversible brain destruction, and it believes treatment is more likely to succeed if started very early, before cognitive impairment or dementia develops and before damage becomes uncontrollable.
Source